Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Jul 09, 2020
Walgreens (WBA, $38.60) misses Q3 earnings estimate

Walgreens (WBA, $38.60) misses Q3 earnings estimate

Walgreens Boots Alliance Inc. reported third quarter earnings that missed analysts' expectations. 

The retail/wholesale pharmacy company’s adjusted earnings for the three months ending in May came in at 83 cents per share, falling short of the Street consensus estimate of $1.18 per share. The EPS was also -43.5% lower from the same period last year.  

Revenues rose +0.1% year-over-year to $34.6 billion, just ahead of analysts' estimates of a $34.35 billion.

Looking ahead, the company projected adjusted earnings in the region of $4.65 per share to $4.75 per share for the year, which  includes a coronavirus impact of between $1.03 and $1.14 per share. 

According to Tickeron, WBA in Downtrend: RSI indicator exits overbought zone

WBA's price could be shifting from an uptrend to a downtrend. Traders may consider selling the ticker or exploring put options. In 21 of 29 cases where WBA's RSI Indicator exited the overbought zone, the price fell further within the following month. The odds of a continued Downtrend are 72%.

Current price $38.50 is below $41.19 the lowest support line found by A.I. Throughout the month of 06/05/20 - 07/08/20, the price experienced a -7% Downtrend. During the week of 06/30/20 - 07/08/20, the stock fell -0.24%.

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on July 06, 2020. Traders may consider selling the ticker, shorting the ticker, or exploring put options. In 55 of 86 cases where WBA's Momentum Indicator fell below the 0 level, its price fell further within the subsequent month. The odds of a continued Downtrend are 64%.

The Moving Average Convergence Divergence (MACD) crossed below the signal line. In 36 of 52 cases where WBA's MACD histogram became negative, the price fell further within the following month. The odds of a continued Downtrend are 69%.

The 10-day Moving Average for this ticker crossed below its 50-day Moving Average on July 07, 2020. This can be construed as a sell signal, indicating that the trend is shifting lower. In 9 of 16 cases where WBA's 10-day Moving Average crossed below its 50-day Moving Average, its price fell further within the subsequent month. The odds of a continued Downtrend are 56%.

The higher Bollinger Band was broken -- a price fall is expected as the ticker heads toward the middle band, which invites the trader to consider selling or shorting the ticker, or exploring put options. In 21 of 35 cases where WBA's price broke its higher Bollinger Band, its price dropped further during the following month. The odds of a continued Downtrend are 60%.

Bullish Trend Analysis

The Stochastic Indicator suggests the ticker price trend may be in a reversal from a Downtrend to an Uptrend. 31 of 61 cases where WBA's Stochastic Indicator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued Uptrend are 51%.

The price moved above its 50-day Moving Average, which indicates a change from a Downtrend to an Uptrend. In 27 of 45 similar backtested cases where WBA's price crossed above its 50-day Moving Average, its price rose further within the subsequent month. The odds of a continued Uptrend are 60%.

The Aroon Indicator entered an Uptrend today. In 61 of 181 similar cases where WBA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 34%.

Fundamental Analysis (Ratings)

Tickeron has a negative outlook on this ticker and predicts a further decline by more than 4.00% within the next month with a likelihood of 61%. During the last month, the daily ratio of advancing to declining volumes was 1.12 to 1.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. WBA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock worse than average.

The Tickeron Price Growth Rating for this company is 59 (best 1 - 100 worst), indicating fairly steady price growth. WBA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 45 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 19 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of 15 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.57) is normal, around the industry mean (2.94). P/E Ratio (10.87) is within average values for comparable stocks, (34.67). Projected Growth (PEG Ratio) (0.51) is also within normal values, averaging (0.57). Dividend Yield (3.47) settles around the average of (1.98) among similar stocks. P/S Ratio (0.29) is also within normal values, averaging (0.66).

Related Ticker: WBA

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a provider of drug store services

Industry DrugstoreChains

Profile
Details
Industry
Drugstore Chains
Address
108 Wilmot Road
Phone
+1 847 315-3700
Employees
331000
Web
https://www.walgreensbootsalliance.com
Interact to see
Advertisement
83.97% Win Rate | 87.10% Annualized Return | $44,879.15 Total Net Profit | Profit Factor: 4.92 | Sharpe Ratio: 1.13
HYMC’s latest sell‑off is part of a broader downtrend that accelerated after the company delayed its PEA, which investors interpreted as an uncertainty event despite no immediate change in reported resources or cash position. Technical indicators such as HYMC breaking above its upper Bollinger Band and then rolling over, along with the Aroon indicator turning down in late February, signaled an elevated risk of a sharp pullback that is now playing out.
DSGR reported quarterly EPS of about 0.18 dollars, badly missing consensus estimates of roughly 0.32–0.33 dollars per share and marking a sharp drop from 0.42 dollars a year ago, which triggered a large negative earnings surprise. Revenue of about 481–482 million dollars came in below expectations near 496 million dollars, and adjusted EBITDA margins compressed to about 7.4% from 9.3% in the prior‑year quarter, highlighting cost and mix pressures.
Shares of CRDO surged +11.90% on March 5, 2026, closing at $114.74 versus a prior close of $102.54. Primary catalyst: Strong Q3 fiscal 2026 earnings reported on March 2, with revenue of $407 million beating consensus estimates by more than $19 million and non-GAAP EPS of $1.07 surpassing forecasts by $0.29.
SPY is trading down approximately -1.30% in Friday premarket, slipping from the prior session's close of $681.31 to around $677–$678. The primary catalyst is a sharply negative February 2026 Nonfarm Payrolls report, which showed a decline of 92,000 jobs — a massive miss versus the consensus forecast of +50,000.
WAL shares dropped approximately 12% in early trading on March 6, 2026, from a prior close of ~$80.74 to roughly ~$71, marking one of the stock's sharpest single-session declines in recent months. The primary catalyst was a surprise announcement that Jefferies Financial Group declined to make a $126.4 million payment owed to Western Alliance Bank under a forbearance agreement tied to the LAM Trade Finance loan portfolio.
MRVL shares surged approximately +15% at the open on March 6, 2026, after closing at $75.68 the prior session. The primary catalyst was a strong Q4 fiscal 2026 earnings report released after the close on March 5, with non-GAAP EPS of $0.80 beating the $0.79 consensus estimate and revenue of $2.219 billion exceeding expectations.
Shares of Day One Biopharmaceuticals surged approximately +65.57% on March 6, 2026, rising from a prior close of $12.78 to an intraday price around $21.16. The primary catalyst driving the session's gains is acquisition and takeover speculation, with reports circulating that Day One may be a buyout target.
GAP shares fell approximately 13% in early trading on March 6, 2026, following the company's Q4 fiscal 2025 earnings report released after market close on March 5. Gap met Wall Street's Q4 estimates on both earnings per share and revenue, but fiscal 2026 guidance fell short of analyst expectations.
Shares of Red Cat Holdings surged approximately +22% in early Friday trading on March 6, 2026, building on a powerful week of momentum in defense drone stocks. The primary catalyst is escalating geopolitical conflict — U.S. and Israeli military strikes on Iran, which dramatically boosted investor appetite for domestic drone and defense technology companies.
The primary catalyst for the decline was the pricing of a secondary offering of roughly 9 million shares at about 22.25 dollars per share by Ingram Holdco, an affiliate of Platinum Equity, with all proceeds going to the selling shareholder and not to Ingram Micro itself. Investors often view such secondary offerings as short‑term bearish because they increase the freely tradable float and signal that a major holder is cashing out part of its stake, even if the company’s operations remain intact.
Rumble reported Q4 2025 revenue of about 27.1 million dollars, below consensus expectations near 29 million dollars and down roughly 10% year over year, confirming that top‑line momentum has stalled. GAAP EPS came in at a loss of around 0.13 dollars, missing analyst estimates by roughly 0.05 dollars and underscoring that the platform remains far from break‑even despite prior cost cuts and efficiency efforts.
Tronox’s Q4 2025 non‑GAAP EPS came in at a loss of about 0.60 dollars, missing expectations by roughly 0.02 dollars, while revenue of around 730 million dollars grew about 8% year over year, showing volume resilience but weak earnings power.
Defense budgets worldwide are surging — global military spending topped $2.2 trillion in 2023, a record high — while semiconductor demand is projected to reach a $1 trillion industry by 2030. At the intersection of these two mega-trends sits one of Tickeron's most strategically focused AI Trading Robots: the XAR, ITA, SOXL – AI Trading Agent (3 Tickers), 15min.
HIMS shares surged approximately +43.85% in premarket trading on Monday, March 9, 2026, rising from a prior close of $15.74 to around $22.80. Primary catalyst: Novo Nordisk officially ended its patent infringement lawsuit against Hims & Hers and announced a landmark partnership to distribute branded Wegovy through the Hims platform at $599/month.
XENE shares surged approximately +45.93% in premarket trading on March 9, 2026, one of the largest single-session moves in the company's history. The primary catalyst: Xenon announced positive topline Phase 3 X-TOLE2 results for its lead drug candidate azetukalner in focal onset seizures (FOS), meeting the primary endpoint with overwhelming statistical significance.
Shares of OLMA dropped approximately 41% in Monday's session, one of the steepest single-day declines in the company's history. The primary catalyst was Roche's Phase 3 persevERA trial failure — a late-stage study of giredestrant, a closely competing selective estrogen receptor degrader (SERD), which missed its primary endpoint of statistically significant improvement in progression-free survival.
RLMD shares surged approximately +40% at the open on March 9, 2026, rising from a prior close of $4.45 to approximately $6.23, driven by a major clinical trial readout. The primary catalyst was the announcement of 12-month interim data from the Phase 2 trial of NDV-01, Relmada's lead oncology candidate, in patients with high-risk non-muscle invasive bladder cancer (NMIBC) — results that significantly exceeded historical benchmarks.
CRCL surged +8.66% on Monday, March 9, 2026, rising from a prior close of $101.94 to trade at $110.77 intraday. The primary catalyst is a landmark stablecoin milestone: Circle's USDC overtook Tether as the dominant stablecoin by transfer volume, accounting for approximately 70% of all stablecoin transfer activity as total stablecoin transfers hit $1.8 trillion in February.
Carnival Corporation (CCL) shares fell approximately -7.60% in Monday's session, dropping from a Friday close of $25.79 to around $23.83. The primary catalyst is a broad market sell-off driven by intensifying recession fears, with the S&P 500 and consumer discretionary names bearing the brunt of the pressure.